Prosecution Insights
Last updated: November 04, 2026
Application No. 18/185,341

CAMPTOTHECIN CONJUGATES

Final Rejection §112
Filed
Mar 16, 2023
Priority
Mar 17, 2022 — provisional 63/321,105 +1 more
Examiner
PIHONAK, SARAH
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Seagan Inc.
OA Round
2 (Final)
61%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
932 granted / 1518 resolved
+1.4% vs TC avg
Strong +42% interview lift
Without
With
+42.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
37 currently pending
Career history
1561
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
39.3%
-0.7% vs TC avg
§102
10.3%
-29.7% vs TC avg
§112
23.2%
-16.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1518 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 31-32, 34, 46-47, 65, 73, 76, and 84 are pending as of the response and amendments filed on 8/5/26. Claims 1-30, 33, 35-45, 48-64, 66-72, 74-75, 77-83, and 85 have been canceled. The rejections under 35 USC 112(b) and 102(a)(1) of record are withdrawn in view of the amendments. The 102(a)(2) and 103 rejections of record are withdrawn as Applicants have stated the subject matter disclosed in WO 2022198232 was commonly owned by Seagan Inc. not later than the effective filing date of the claimed invention. In view of the amendments, new rejections are made under 35 USC 112(b), discussed below. Claims 31-32, 34, 46-47, 65, 73, 76, and 84 were examined. Claims 46, 65, 73, and 84 are rejected. Claims 31-32, 34, 47, and 76 are allowed. Claim Rejections-35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 46, 65, 73, and 84 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The second page of claim 46 recites “a maleimide moiety ….”, but doesn’t recite which variable corresponds to this moiety. It appears that some of the claim language is missing from this portion. As it’s uncertain what the maleimide moiety corresponds to, the claim is indefinite. Claim 65 contains the group Rb6 as an attachment group for Formula D0b, however, the definition of Rb6 has been deleted from the amended claim. Therefore, the claim scope is indefinite, as it’s uncertain what functional group(s) constitute Rb6. Claims 73 and 84 are rejected as these claims depend from claim 65. Reasons for Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: the camptothecin derivatives of the claims are not taught or suggested by the prior art. Ryan et. al., WO 2012125232 A1 (publ. 9/20/2012) represents the most relevant prior art. Ryan teaches campothecin derivatives and camptothecin linker conjugates, and teaches the camptothecin core of the following formula: PNG media_image1.png 200 400 media_image1.png Greyscale , wherein n is 0 or 1, and R3 and R4 can together form a 5- or 6-membered ring. However, Ryan only provides guidance in which R3 and R4 form rings having two ring oxygen atoms, which are excluded by the instant claims. Additionally, Ryan doesn’t provide sufficient guidance to arrive at the specific selection of camptothecin substituents as claimed, or camptothecin-linker conjugates having one of the recited formulas as claimed. Information Disclosure Statements The IDS filed on 8/6/26 have been considered. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. SARAH . PIHONAK Primary Examiner Art Unit 1627 /SARAH PIHONAK/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Mar 16, 2023
Application Filed
May 05, 2026
Non-Final Rejection mailed — §112
Aug 05, 2026
Response Filed
Sep 23, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778920
METHODS OF TREATING SJÖGRENS SYNDROME
3y 11m to grant Granted Nov 03, 2026
Patent 12773395
O-ACETYLSERINE FOR THE USE THEREOF IN THE PREVENTION AND TREATMENT OF GLUCOSE INTOLERANCE AND THE ASSOCIATED DISEASES
3y 6m to grant Granted Oct 27, 2026
Patent 12773410
EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
2y 10m to grant Granted Oct 27, 2026
Patent 12760367
TREATMENT OF ATOPIC DERMATITIS WITH TRADIPITANT
3y 11m to grant Granted Oct 13, 2026
Patent 12758557
SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES
3y 3m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+42.3%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1518 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month